Skip to main content

Table 1 Clinical characteristics of patients

From: Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients

Patient ID Cohort Atovaquone Interval between scans (days) PET tracer Age (years)/sex TNM staging Tumour volume (mL)
10001 1 Yes 13 FMISO 58/M T3 N0 M0 89.5
10004 1 Yes 8 FAZA 71/F T4 N3 M0 184.9
10005 1 Yes 14 FMISO 72/M T2a N2 M0 61.0
10,006 1 Yes 14 FMISO 69/M T4 N2 M0 179.5
10008 1 Yes 10 FMISO 77/F T2a N0 M0 17.8
10009 1 Yes 14 FMISO 78/M T3 N0 M0 59.3
10010 1 Yes 13 FMISO 70/M T4 N2 M0 371.1
10011 1 Yes 8 FMISO 77/F T4 N0 M0 24.6
10013 1 Yes 9 FMISO 54/F T1c N3 M0 15.5
10014 1 Yes 13 FMISO 55/F T3 N0 M0 42.2
10016 1 Yes 14 FMISO 57/F T2a N0 M0 30.6
10019 1 Yes 14 FMISO 58/M T4 N0 M0 366.9
10020 1 Yes 14 FMISO 73/M T3 N0 M0 85.3
10022 1 Yes 14 FMISO 65/F T2b N1 M0 45.9
10023 1 Yes 8 FMISO 58/F T3 N0 M0 33.4
10024 2 No 13 FMISO 68/M T3 N1 M0 45.8
10025 2 No 14 FMISO 71/M T4 N0 M0 40.8
10028 2 No 14 FMISO 53/M T3 N1 M0 20.6
10029 2 No 14 FMISO 87/M T2b N1 M0 24.1
10030 2 No 7 FMISO 57/M T3 N2 M0 243.0
10031 2 No 15 FMISO 58/F T3 N0 M1b 5.4
10033 2 No 14 FMISO 75/M T1c N0 M0 6.3
10034 2 No 14 FMISO 63/M T1b N1 M0 43.7
10037 2 No 11 FMISO 70/M T2a N0 M0 19.1
10039 2 No 14 FMISO 67/M T4 N0 M0 144.8
10041 2 No 7 FMISO 61/M T2a N1 M0 20.0
10043 2 No 7 FMISO 69/F T4 N0 M0 80.7
10044 2 No 8 FMISO 62/F T3 N1 M0 45.3
10045 2 No 2 FMISO 81/M T3 N0 M0 185.4
10046 2 No 14 FMISO 70/M T3 N0 M0 57.5